. 2016 Jun 30;6(6):e011714. doi: 10.1136/bmjopen-2016-011714

Table 1.

Baseline characteristics of the patients in the trials included in the meta-analysis

Author	Treatment regimen	Number of patients	Male/female	Smoking history (never/previous/ current)	ECOG PS(0/1/2)	Histology (large-cell carcinoma/adenocarcinoma/ squamous/others)	Line of treatment
Herbst et al¹³	Bev 15 mg/kg(3-week cycle)+erlo 150 mg per day	319	171/148	34/237/48	129/166/23	23/242/11/43/38	Second-line
	Erlo 150 mg per day+placebo 15 mg/kg	317	170/147	33/212/72	121/176/20	25/235/17/40
Ciuleanu et al¹⁴	Bev 15 mg/kg(3-week cycle)+erlo 150 mg per day	63	37/26	21/20/11	28/35/0	NR	First-line
	Bev15 mg/kg (3-week cycle)+(gemcitabine/cisplatin or carboplatin/paclitaxel)	61	36/25	23/14/24	20/41/0	NR
Seto et al³²	Bev 15 mg/kg+erlo 150 mg per day	77	30/45	42/9/24	43/32/0	0/74/1/0	First-line
	Erlo 150 mg per day	77	26/51	45/6/26	41/36/0	1/76/0/0
Herbst et al³³	Bev 15 mg/kg(3-week cycle)+erlo 150 mg per day	39	17/22	NR	19/20/0	0/32/7/0	Second-line
	Bev 15 mg/kg(3-week cycle)+chemo(docetaxel or pemtrexed)	40	23/17	NR	19/21/0	9/30/1/0
Johnson et al³⁴	Bev 15 mg/kg(3-week cycle)+erlo 150 mg per day	370	193/177	61/180/129	180/190/0	30/301/11/28	Second-line
	Bev15 mg/kg(3-week cycle)+placebo	373	196/177	66/178/129	173/198/1	26/309/6/32

Bev, bevacizumab; erlo, erlotinib; ECOG PS, Eastern Cooperative Oncology Group performance status; NR, not reported.